Beactica Overview

  • Founded
  • 2006
Founded
  • Status
  • Private
  • Employees
  • 12
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $294K
Latest Deal Amount
  • Investors
  • 8

Beactica General Information

Description

Developer of drug discovery platform designed to facilitate the treatment for glioblastoma and other cancers. The company's LSD1-protein-based therapeutics regulates the expression of disease-associated proteins in order to change the chromatin configuration that governs regulation of DNA transcription and improve immune system's ability to fight cancer, enabling medical practitioners to treat patients with cancer with improved efficiency and lesser risks.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Virdings allé 2
  • 754 50 Uppsala
  • Sweden
+46 018-56 00 00

Beactica Timeline

2017201820192020
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Beactica Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 18-Jun-2019 $294K Completed Generating Revenue
7. Later Stage VC 04-Jun-2019 Completed Generating Revenue
6. Grant 23-Mar-2018 000.00 Completed Generating Revenue
5. Later Stage VC 15-Dec-2014 Completed Generating Revenue
4. Accelerator/Incubator Completed Generating Revenue
3. Grant 20-Nov-2014 00000 Completed Generating Revenue
2. Grant 14-Sep-2007 $187K Completed Startup
1. Early Stage VC 22-Nov-2006 Completed Startup
To view Beactica’s complete valuation and funding history, request access »

Beactica Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of drug discovery platform designed to facilitate the treatment for glioblastoma and other cancers. The compan
Drug Discovery
Uppsala, Sweden
12 As of 2016
0000000000

00000000

commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu
0000000000000
Seattle, WA
00 As of 0000
00000
0000 0000-00-00
00000000 00000

00000000

trud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in
0000000000000
Gaithersburg, MD
00 As of 0000
000.00
000 0000-00-00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Beactica Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Silverback Therapeutics Venture Capital-Backed Seattle, WA 00 00000 00000000 00000
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
0000000 Venture Capital-Backed Indianapolis, IN 0 000.00 0000000000 0 000.00
0000000000 Venture Capital-Backed Abingdon, United Kingdom 000 00000 00000000000 00000
You’re viewing 5 of 30 competitors. Get the full list »

Beactica Executive Team (4)

Name Title Board Seat Contact Info
Per Kallblad Ph.D Co-Founder & Chief Executive Officer
Jan-Olof Karlsson Chief Financial Officer
Ulf Bremberg Ph.D Chief Scientific Officer
To view Beactica’s complete executive team members history, request access »

Beactica Board Members (10)

Name Representing Role Since
Erik Walldén Self Board Member 000 0000
Gisela Sitbon Ph.D Self Chairman 000 0000
Hakan Wickholm Self Board Member 000 0000
Helena Danielson Ph.D Beactica Co-Founder, Consultant & Board Member 000 0000
Maarten de Château Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Beactica Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Beactica Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
SWElife Accelerator/Incubator 000 0000 000000 0
M2Capital PE/Buyout Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Unionen Venture Capital Minority 000 0000 000000 0
European Commission Government 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »